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Exposure to Melan-A/MART-126-35 
tumor epitope specific CD8+T cells 
reveals immune escape by affecting 
the ubiquitin-proteasome system 
(UPS)
Frédéric Ebstein1,*, Martin Keller1,*, Annette Paschen2, Peter Walden3, Michael Seeger1, 
Elke Bürger1, Elke Krüger1, Dirk Schadendorf2, Peter- M. Kloetzel1,5 & Ulrike Seifert1,4
Efficient processing of target antigens by the ubiquitin-proteasome-system (UPS) is essential for 
treatment of cancers by T cell therapies. However, immune escape due to altered expression of IFN-
γ-inducible components of the antigen presentation machinery and consequent inefficient processing 
of HLA-dependent tumor epitopes can be one important reason for failure of such therapies. Here, we 
show that short-term co-culture of Melan-A/MART-1 tumor antigen-expressing melanoma cells with 
Melan-A/MART-126-35-specific cytotoxic T lymphocytes (CTL) led to resistance against CTL-induced lysis 
because of impaired Melan-A/MART-126-35 epitope processing. Interestingly, deregulation of p97/VCP 
expression, which is an IFN-γ-independent component of the UPS and part of the ER-dependent protein 
degradation pathway (ERAD), was found to be essentially involved in the observed immune escape. 
In support, our data demonstrate that re-expression of p97/VCP in Melan-A/MART-126-35 CTL-resistant 
melanoma cells completely restored immune recognition by Melan-A/MART-126-35 CTL. In conclusion, 
our experiments show that impaired expression of IFN-γ-independent components of the UPS can 
exert rapid immune evasion of tumor cells and suggest that tumor antigens processed by distinct UPS 
degradation pathways should be simultaneously targeted in T cell therapies to restrict the likelihood of 
immune evasion due to impaired antigen processing.
The generation of antitumor cytotoxic T cell (CTL) response involves the processing and presentation of tumor 
antigens onto MHC class I molecules1,2. These specialized T cells can detect target cells that endogenously express 
protein molecules (i.e. mutated, over-expressed and/or tissue differentiation antigens) and subsequently remove 
these cells from the body3,4. The vast majority of peptides presented by MHC class I molecules at the cell surface 
for recognition by specific cytotoxic T-cells (CTL) is generated by the ubiquitin-proteasome system (UPS) with 
its central multicatalytic proteinase complex, the proteasome5,6. Peptides generated by the proteasome system are 
transported by TAP proteins (transporter associated with antigen presentation) into the ER where peptides of 
appropriate length and affinity will bind to MHC class I proteins to be presented at the cell surface for immune 
recognition by CTL7–9.
The standard 20S proteasome (s-20S proteasome) with its active site β -subunits β 1, β 2 and β 5 represents the 
central catalytic unit of the UPS and the catalytic core of the 30S proteasome which is built by the association 
of two 19S regulator complexes with the 20S core complex. IFN-γ induces the synthesis of alternative catalytic 
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immunosubunits (i-subunits), i.e. β 1i/LMP2, β 2i/MECL1 and β 5i/LMP7 and the concomitant formation of 
immunoproteasome (i-proteasome) subtypes8–10. The 30S proteasome complexes are responsible for the deg-
radation of proteins in the nucleus and the cytosol, which are marked for degradation by a poly-ubiquitin chain 
and consequently recognized by specific subunits of the 19S regulator complex. A special problem arises for the 
degradation and processing of membrane proteins, which are co-translationally transported into the endoplas-
mic reticulum (ER). These proteins, if misfolded or mutated, are re-translocated to the cytosolic side of the ER 
to be degraded by the 30S proteasome complex in an ubiquitin-dependent manner11–13. This process is called 
ER associated degradation pathway (ERAD) and essentially requires the so-called ERAD-complex within the 
ER-membrane. This complex is composed of a number of different proteins including Derlin, VIMP, Herp and 
the E3-ligase HRD114,15. Functionally associated with the ERAD pathway on the cytosolic site of the ER is the p97/
VCP ATPase complex. The p97/VCP complex binds and extracts poly-ubiquitinated proteins from the membrane 
making them available for proteasomal degradation at the cytosolic site of the ER16,17.
Efficient processing and generation of the target antigenic peptides by the UPS is essential for treatment 
of cancers by T-cell therapy. However, immune escape due to inefficient processing of HLA dependent tumor 
epitopes can be one important reason for failure of such therapies. It is known that tumors can down-regulate or 
completely lose expression of tumor antigens and HLA class I molecules, thereby escaping from T cell recogni-
tion18,19. Modulation of the UPS has also been observed and, in particular, the expression of the IFN-γ inducible 
components of the UPS such as PA28α /β and the i-subunits β 1i/LMP2 and β 5i/LMP7 were found to be altered in 
tumor cells, affecting both the quantity and in certain cases also the quality of the generated epitopes20–22. In some 
cases, a deficient expression of proteasome components could be reverted in the presence of IFN-γ , thereby also 
reconstituting MHC class I surface expression23. However, due to the complexity of the UPS and its associated 
pathways, only a few immune escape mechanisms have been characterized so far, although knowledge of these 
mechanisms is a prerequisite for the improvement of cancer immunotherapy.
To identify novel mechanisms by which tumors can become refractory to immune elimination, human mela-
noma cells expressing the transmembrane Melan-A/MART-1 tumor antigen were exposed to two rounds of brief 
co-culture with Melan-A/MART-126-35-specific CTL. Immune selected melanoma cell clones, being resistant to 
lysis by Melan-A/MART-126-35 CTL were investigated for the underlying mechanism focusing on the role of the 
proteasomal antigen processing machinery. We detected a deregulated ERAD pathway as a so far unknown mech-
anism for immune escape of melanoma cells. In particular, the essential non-inducible ERAD component p97/
VCP has been found to be down regulated in CTL-resistant melanoma cells. Rescue experiments reconstituting 
p97/VCP expression in melanoma cells resulted in enhanced Melan-A/MART-126-35 epitope recognition, under-
lining the in vivo functional relevance of our results.
Results
Selection of melanoma cell clones resistant to CTL-mediated lysis by Melan-A/MART-126-35-
specific CTL. To identify unknown immune evasion mechanisms allowing melanoma cells to circumvent 
recognition by specific CTL, the human HLA-A*0201-positive melanoma cell line UKRV-Mel-15a expressing 
the transmembrane tumor antigen Melan-A/MART-120,24,25 was co-incubated with an HLA-A*0201-restricted 
Melan-A/MART-126-35-specific CTL clone. Surviving UKRV-Mel-15a cells were exposed to two or three rounds of 
CTL co-culture selecting for resistant tumor cell clones. To exclude resistance due to HLA or antigen down-reg-
ulation, UKRV-Mel-15a cells were analyzed for HLA-A*0201 and Melan-A/MART-1 expression by flow cytom-
etry. As shown in Fig. 1A, three rounds of co-culture resulted in considerable HLA-A*0201 down-regulation. 
We therefore decided to apply only two rounds of CTL co-culture for the selection of resistant melanoma clones, 
because under these conditions the HLA-A*0201 and Melan-A/MART-1 expressions of the surviving clones was 
similar or even higher than those of the parental UKRV-Mel-15a cell line (Fig. 1A).
We next tested the ability of the UKRV-Mel-15a derived clones to present the Melan-A/MART-126-35 epitope 
by exposing them to Melan-A/MART-126-35-specific CTL in a 6-h antigen presentation TNF-α assay. Exposing 
Melan-A/MART-126-35 CTL to peptide-pulsed T2 cells but not unloaded T2 cells resulted in increased produc-
tion of TNF-α , thereby confirming the specificity of our read-out system (Fig. 1B, right panel). Of more than 30 
UKRV-Mel-15a clones, only the clones 6, 18 and 30 exhibited significantly impaired recognition by Melan-A/
MART-126-35-specific CTL and therefore were chosen for further analysis (Fig. 1B). Importantly, both TNF-α 
release and cytolysis by Melan-A/MART-126-35-specific CTL could be restored upon exogenous loading of 
UKRV-Mel-15a clones with synthetic Melan-A/MART-126-35 peptide (Fig. 1C,D). This demonstrates that the 
HLA-A*0201 expression level on these clones was not rate limiting for immune recognition and that the observed 
immune escape was not due to resistance of the three selected melanoma cell clones against CTL-induced 
cytolysis.
Down-regulation of constituents of the antigen processing machinery in tumor cells and concomitant 
impaired epitope generation and presentation is a well-known evasion mechanism described for a variety of 
different human tumors22,23,26,27. However, as mentioned above, the expression of these components can be 
restored following IFN-γ treatment. Importantly, the expression levels of TAP1 and TAP2 as well as of the three 
proteasome immunosubunits in UKRV-Mel-15a clones were comparable to those of the non-selected parental 
UKRV-Mel-15a cells (Fig. S1). Only the clone 30 exhibited some impairment in the inducible expression of the 
i-subunits, as evidenced by its incapacity to up-regulate β 1i/LMP2, β 2i/MECL and β 5i/LMP7 in response to 
IFN-γ . This suggests that the observed resistance of the selected UKRV-Mel-15a clones to CTL-mediated lysis 
was not due to an altered IFN-γ signaling pathway. This notion is supported by the observation that IFN-γ expo-
sure failed to modify the phenotype of the UKRV-Mel-15a clones 6, 18 and 30 (Fig. 1E).
Deregulation of ERAD components in resistant melanoma cell clones. To determine which of the 
UPS components and its associated pathways was responsible for the down-regulation of Melan-A/MART-126-35 
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epitope presentation; UKRV-Mel-15a clones were subjected to microarray gene expression analysis focusing on 
more than 1000 components of the antigen processing machinery. Interestingly, all three selected UKRV-Mel-15a 
clones displayed considerable alterations in the expression levels of a set of mRNAs encoding p97/VCP, VIMP, 
HERP and Derlin-1 (Table 1) and thus proteins whose functions are related to or directly connected with the 
ER-dependent degradation (ERAD) pathway28. Because cellular protein levels strongly depend on the rate of 
synthesis and their half-lives, expression levels of mRNAs and corresponding detectable protein levels do not nec-
essarily correlate. Therefore, we next analyzed the expression levels of the affected ERAD-associated proteins by 
Western blot. As shown in Fig. 2A,B, all three resistant UKRV-Mel-15a clones revealed a strong down-regulation 
of the ERAD components p97/VCP, which is essential for the extraction of poly-ubiquitinated substrates from 
the ER29, and VIMP, which is a seleno-protein associated with p97/VCP as well as with the membrane pro-
tein Derlin-117. In contrast, slightly increased expression levels were found for HERP and Derlin-1 (Fig. 2A,B). 
Importantly, there was no substantial loss of the Melan-A/MART-1 antigen expression in the UKRV-Mel-15a 
Figure 1. Analysis of melanoma cell clones resistant to MART-126-35-specific CTL lysis. (A) Immune selected 
melanoma cell clones derived from co-cultivation of UKRV-Mel-15a cells (Mel 15) with Melan-A/MART-126-35 
specific CTL were analyzed for HLA-A*0201 and MART-1 expression by flow cytometry after two (triangle) 
and three (rhomb) selection cycles. Data are presented as fold changes compared to the parental UKRV-Mel-15a 
cell line (circle) whose HLA-A*0201 and Melan-A/MART-1 expression levels were set to 1.  
(B) UKRV-Mel-15a clones obtained after two rounds of immune selection, were tested for their ability to 
present the Melan-A/MART-126-35 epitope. UKRV-Mel-15a clones were co-cultured for 6 h with Melan-A/
MART-126-35 specific CTL, whose activation was determined by measuring the TNF-α -content in the 
supernatants by ELISA. The UKRV-Mel-15a clones 6, 18 and 30 (black columns) exhibited a strongly reduced 
capacity of presenting Melan-A/MART-126-35 (*p < 0.05, Student’s t test) and were therefore selected for 
further analysis. T2 cells loaded with 5 μ M of the Melan-A/MART-126-35 synthetic peptide were included as 
positive control (right panel). **p < 0.01 vs unloaded T2 cells (Student’s t test). (C) The comparability of the 
HLA-A*0201 expression level across the three immune selected UKRV-Mel-15a clones was further verified 
by analyzing their capacity to stimulate Melan-A/MART-126-35 specific CTL when loaded with 5 μ M of the 
Melan-A/MART-126-35 peptide. CTL activation was determined in a 6-h TNF-α release assay. Error bars 
represent standard deviation (n = 2). *p < 0.05 vs UKRV-Mel-15a parental cells (Student’s t test). (D) The 
sensitivity of the three UKRV-Mel-15a clones to lysis by Melan-A/MART-126-35-specific CTL was tested in a51Cr 
release assay (E:T 10:1). Positive control consisted in UKRV-Mel-15a clones 6, 18 and 30 exogenously pulsed 
with 5 μ M of the Melan-A/MART-126-35 peptide. **p < 0.01 vs the UKRV-Mel-15a parental cell line (Student’s t 
test). (E) The effect of IFN-γ on the presentation of Melan-A/MART-126-35 by the UKRV-Mel-15a clones 6, 18 
and 30 was evaluated in a 6-h TNF-α CTL assay. To this end, cells were treated with IFN-γ at 200 U/ml for 48 h 
prior to an exposure to Melan-A/MART-126-35 CTL and measurement of the released TNF-α by ELISA. Error 
bars represent standard deviation (n = 2). **p < 0.01 vs UKRV-Mel-15a parental cells (Student’s t test). The 
experiments shown are representative of at least two.
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clones 6, 18 and 30. These data therefore suggested that deregulated expression of ERAD components might be 
causative for the impaired Melan-A/MART-126-35 epitope generation and presentation by the three UKRV-Mel-
15a clones.
p97/VCP is a prerequisite for Melan-A/MART-126-35 epitope generation. Apart from the first 
N-terminal amino acid residue which is directed to the luminal compartment, the entire Melan-A/MART-126-35 
10-mer epitope is embedded within the Melan-A/MART-1 transmembrane domain30 (Fig. 3A). Therefore, for 
proteasome-dependent antigen processing, the Melan-A/MART-1 protein must be retro-translocated into the 
cytosol. We next aimed to evaluate the impact of VIMP and HERP on Melan-A/MART-126-35 epitope generation 
independently of the Melan-A/MART-1 endogenous expression level. To this end, both of these ERAD compo-
nents were knocked down by siRNA in the Ma-Mel-91-melanoma cell line (Melan-A/MART-1−/HLA-A*0201+) 
which was subsequently engineered to express the Melan-A/MART-1 antigen. Strikingly and as illustrated in 
Fig. 3B, gene silencing of either VIMP or HERP resulted in a substantial reduced presentation of the Melan-A/
MART-126-35 epitope. Because p97/VCP expression was also found to be significantly reduced in our selected 
UKRV-Mel-15a clones 6, 18 and 30, we next tested its involvement in Melan-A/MART-126-35 epitope genera-
tion by expressing a dominant negative mutant of p97/VCP (p97QQ), which abrogates cellular p97/VCP func-
tion16. Interestingly, although the expression of p97QQ had virtually no effect on cell viability (data not shown), 
it almost completely abrogated Melan-A/MART-126-35 epitope generation, whose levels, under these conditions, 
were quite similar to those observed when proteasomes were inhibited with epoxomicin (Fig. 3C). Accordingly, 
CHX-based chase experiments show that p97/VCP silencing resulted in a significant stabilization of the Melan-A/
MART-1 protein (Fig. 3D). It is to note, that neither the down-regulation of VIMP or HERP by siRNA nor the 
plasmid-mediated transfection of p97/VCP or p97QQ substantially affected the expression level of the Melan-A/
MART-1 full-length protein (Fig. S2).
Melan-A/MART-126-35 epitope recognition is rescued by overexpression p97/VCP. The obser-
vation, that the inhibition and/or gene silencing of VIMP and p97/VCP almost completely abrogated Melan-A/
MART-126-35 epitope presentation and that both proteins were found to be down-regulated in CTL-resistant 
UKRV-Mel-15a clones suggests that both or one of them may be causative for the observed immune evasion. 
Therefore, we next sought to determine whether the immune escape of the UKRV-Mel-15a clones was reversible 
by restoring p97/VCP or VIMP expression.
To this end, we performed MHC class I presentation rescue experiments by transfecting the UKRV-Mel-
15a clone 18 with expression vectors encoding full-length p97/VCP or VIMP proteins. As shown in Fig. 4A,B, 
re-expression of p97/VCP restored stimulation of Melan-A/MART-126-35-specific T cells to levels comparable 
to those detected upon exposure to the parental UKVR-Mel-15a cell line, demonstrating that the observed 
down-regulated expression of p97/VPC was indeed responsible for the observed immune escape of the 
UKRV-Mel-15a Mel-15 clones. Accordingly, RNAi-mediated down-regulation of p97/VCP in the parental 
UKVR-Mel-15a cell line was accompanied by severe impairment of Melan-A/MART-126-35 presentation (Fig. S3), 
further confirming that p97/VCP ensures the supply of Melan-A/MART-126-35 antigenic peptides under nor-
mal conditions. This also suggests that the observed emergence of resistant clones following Melan-A/MART-
126-35 CTL exposure is most likely driven by the spontaneous loss of p97/VCP expression in the heterogeneous 
UKRV-Mel-15a parental melanoma cell population or a selective enrichment of cells expressing low levels of 
p97/VCP. In contrast, over-expression of the p97/VCP recruiting membrane protein VIMP failed to rescue the 
Melan-A/MART-126-35 epitope presentation (Fig. 5A,B). This, however, is in agreement with a previous report 
showing that the over-expression of VIMP in COS cells alters ER morphology which may cause dysfunction of 
the ERAD pathway17.
Down-regulation of p97/VCP is also an immune escape mechanism in Ma-Mel-63a cells. The 
data obtained so far provide strong evidence that impaired expression of p97/VCP and subsequent dysfunc-
tion of the ERAD pathway was causative for the observed immune escape of CTL challenged UKVR-Mel-15a 
cells. Nevertheless, the possibility remained that this may represent an isolated case due to unknown specific 
features of the UKVR-Mel-15a cells. Therefore, we performed a second independent experimental analysis using 
the Melan-A/MART-1+, HLA-A*0201 melanoma cell line Ma-Mel-63a. As shown in Fig. 6A, Ma-Mel-63a cells 
Gene Clone 6 Clone 18 Clone 30
p97/VCP 0.622 0.513 0.451
VIMP 0.768 0.656 0.779
HERP 0.852 0.742 1.675
Derlin-1 1.971 1.954 1.991
Table 1.  The immune challenge of the UKRV-Mel-15a melanoma cell line with Melan-A/MART-126-35-
specific CTL results in altered expression of ERAD-related genes. Following two rounds of exposure with 
Melan-A/MART-126-35-specific CTL, the UKRV-Mel-15a melanoma cells resistant to cell lysis were further 
cultivated and cloned by limiting dilution. The transcription profile of the clones 6, 18 and 30 was analyzed by 
microarrays and compared to that of the untreated UKRV-Mel-15a parental cell line (shown is the expression 
ratio of the mRNA expression levels relative to that of the UKRV-Mel-15a parental cell line). Four genes 
belonging to the ERAD pathway (i.e. p97/VCP, VIMP, HERP and Derlin-1) were identified as being strongly 
altered in the UKRV-Mel-15a clones 6, 18 and 30.
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expressed and efficiently presented the Melan-A/MART-126-35 tumor epitope, as revealed by TNF-α -release 
assays. Importantly, overexpression of p97/VCP did not further improve the Melan-A/MART-126-35 epitope pres-
entation, suggesting that the ERAD pathway was fully functional in these cells. This notion was also supported 
by immunoblotting experiments revealing normal expression levels of the ERAD associated components (data 
not shown).
Following the same experimental conditions, Ma-Mel-63a cells were challenged twice in short-term co-culture 
with Melan-A/MART-126-35-specific CTL. The Ma-Mel-63a clones resistant to CTL mediated lysis were further 
cultivated and assessed for their capacity of presenting the Melan-A/MART-126-35 epitope. Of the 33 Ma-Mel-
63a clones, 3 clones (i.e. clones 9, 15 and 26) exhibited substantial impaired recognition by Melan-A/MART-
126-35 CTL when compared with the unchallenged parental Ma-Mel-63a cell line (Fig. 6B). Strikingly, all three 
clones also displayed reduced p97/VCP expression (Fig. 6C). Of these, clone 26 could not be further analyzed 
because it lost its endogenous Melan-A/MART-1 expression (data not shown). The Ma-Mel-63a clone 15 was 
finally selected for p97/VCP rescue experiments, because it revealed an almost unaltered expression level of the 
ERAD components VIMP, HERP or Derlin-1 as well as a normal expression of the IFN-inducible i-subunits 
and TAP1/2 (Figs 7A and S4). As shown in Fig. 7B,C, overexpression of p97/VCP almost completely restored 
Melan-A/MART-126-35 epitope presentation. These data show that impaired expression of the ERAD component 
p97/VCP upon immune challenge with Melan-A/MART-126-35-specific T-cells is an universal event that allows 
melanoma cells to escape CTL-mediated cell death.
Discussion
There is mounting clinical evidence that T-lymphocytes play a central role in the regression of melanoma in vivo 
and that adoptive transfer of cultured T cells from tumor infiltrating lymphocytes may result in tumor regres-
sion31. However, loss of MHC class I expression has been reported to render tumors resistant to adoptive T-cell 
therapy32. In fact, analysis of tumor cells also revealed a down-regulation of the IFN-γ -inducible antigen pro-
cessing machinery33–37. It is not clear how frequent immune escape of tumors upon T cell pressure results in 
the irreversible loss of IFN-γ sensitivity. Studies of tumor cell lines showed that, in most cases, the expression 
of down-regulated components involved in MHC class I antigen presentation was restored by IFN-γ treatment. 
Nevertheless, immune evasion of tumor cells upon T cell pressure still remains a problem and very little is known 
about escape mechanism connected with antigen processing. Our experiments show that co-cultivation of the 
Figure 2. The expression levels of components of the ERAD pathway are altered in immune selected 
UKRV-Mel-15a cell clones. (A) The UKRV-Mel-15a clones 6, 18 and 30 as well as the UKRV-Mel-15a parental 
cell line were subjected to protein extraction. Whole cell extracts were resolved by SDS-PAGE followed by 
Western blotting using antibodies specific for p97/VCP, VIMP, HERP, Melan-A/MART-1 and Derlin-1, as 
indicated. Equal protein loading was ensured by probing the membrane with anti-GAPDH antibody.  
(B) Fold changes of the expression levels of p97/VCP, HERP, VIMP and Derlin-1 between the UKRV-Mel-
15a parental cell line and the UKRV-Mel-15a clones 6, 18 and 30, as visualized by densitometric analysis. The 
band intensity of each protein was normalized to that of GAPDH and subsequently expressed as fold-changes 
compared to the UKRV-Mel-15a parental cell line which was set at 1.
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melanoma UKRV-Mel-15a and Ma-Mel-63a cells with Melan-A/MART-126-35 CTL led in both instances to the 
isolation of several melanoma cell clones, which revealed impaired presentation of the Melan-A/MART-126-35 
antigenic peptide (Figs 1 and 6). However, immunoblot analyses failed to provide evidence that the expression 
of any of the known IFN-γ inducible components of the antigen processing and presentation machinery was 
significantly modified (Figs S1 and S4) and therefore did not explain the observed immune escape of the resistant 
UKRV-Mel-15a and Ma-Mel-63a clones.
The UPS with its more than 1000 protein components plays a central role in the generation of tumor epitopes 
presented by MHC class I molecules. Many of these may be directly or indirectly involved in the regulated pro-
teasome dependent degradation of the Melan-A/MART-1 protein. Because of this complexity, we focused our 
analysis in particular on components of the ER associated degradation (ERAD) pathway known to be involved in 
the degradation of membrane-associated tumor antigens such as tyrosinase38. Indeed, our cDNA array analyses 
of melanoma cells resistant to cytolysis by Melan-A/MART-126-35-specific CTL revealed several of the known 
Figure 3. Melan-A/MART-126-35 epitope presentation is ERAD-dependent. (A) Schematic representation 
of the Melan-A/MART-126-35 epitope which is entirely localized within the transmembrane domain, except for 
the first amino acid residue. (B) The melanoma cell line Ma-Mel-91 (Melan-A/MART-1−, HLA-A*0201) was 
exposed to non-targeting (control) siRNA or siRNA directed against VIMP or HERP1 prior to a subsequent 
transfection with an expression vector encoding the wild-type full-length Melan-A/MART-1 tumor antigen. 
The ability of these cells to present the Melan-A/MART-126-35 epitope was evaluated in a 6 h TNF-α release 
assay upon exposure to Melan-A/MART-126-35 CTL. The content of TNF-α in the supernatants was measured 
by ELISA. *p < 0.05 vs Ma-Mel-91 cells expressing Melan-A/MART-1 and exposed to control siRNA (Student’s 
t test) (C) The impact of p97/VCP on Melan-A/MART-126-35 presentation was evaluated by transfecting Ma-
Mel-91 cells with Melan-A/MART-1 in combination with either wild-type p97/VCP or a dominant negative 
mutant of p97/VCP (p97QQ). After 24 h of transfection, the cells were tested for their capacity to present the 
Melan-A/MART-126-35 antigenic peptide by cultivating them in the presence of Melan-A/MART-126-35 CTL and 
followed by subsequent measurement of TNF-α by ELISA. In addition, proteasome dependency of Melan-A/
MART-126-35 epitope generation was demonstrated by treating the Ma-Mel-91 cells transfected with the 
Melan-A/MART-1 expression plasmid with 1 μ M of the proteasome inhibitor epoxomicin for 4 h. As control, 
Ma-Mel-91 cells were loaded with the Melan-A/MART-126-35 synthetic peptide or were transfected with the 
pcDNA3.1 plasmid and loaded with the Melan-A/MART-1 peptide. *p < 0.05 vs Melan-A/MART-1-expressing 
Ma-Mel-91 cells and ##p < 0.01 vs unloaded Ma-Mel-91 cells (Student’s t test) (D) Silencing of p97/VCP by 
siRNA results in stabilization of the Melan-A/MART-1 protein expression. HeLa cells were exposed to either 
non-targeting (control) or p97/VCP siRNA for 24 h prior to a subsequent 24 h transfection with an expression 
plasmid encoding wild-type Melan-A/MART-1 and subjected to CHX-based chase assay. Cells were collected 
after 1, 2, 4 and 8 h and Western blot analysis was performed for each time point using antibodies specific for 
Melan-A/MART-1, p97/VCP and GAPDH (loading control).
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ERAD components to be down regulated in these cells. Interestingly, the most reproducible down-regulation was 
observed for the AAA ATPase p97/VCP (Table 1). Importantly, the down-regulation of p97/VCP was observed 
in two independent melanoma cell lines, indicating that such effect was not cell line-specific but rather a more 
general phenomenon in response to CTL exposure (Figs 2A and 6C). The essential and critical role of ERAD in 
the ubiquitin-dependent degradation of membrane proteins and, as such, in the generation of antigenic peptide 
derived from membrane proteins is well documented39,40. Given the high number of membrane-bound proteins 
among melanoma-associated antigens, an active contribution of ERAD in tumor surveillance is very likely. For 
example, a functional ERAD pathway has been reported to be a prerequisite for the breakdown of the tyrosi-
nase antigen38,41. This is also true for secretory proteins such as the pro-insulin auto-antigen42. Interestingly, the 
ERAD-mediated degradation of tyrosinase occurs in an EDEM1-dependent fashion, while that of pro-insulin 
mainly relies on Derlin-2, HRD1 and p97/VCP. The observation that ERAD substrates do not necessarily rely 
on the same components implies a strong heterogeneity and plasticity of the ERAD pathway. This point is of 
considerable importance, as it suggests that the loss of one particular ERAD-associated protein in tumors might 
not necessarily cause immune escape. An exception, however, is p97/VCP which is essentially required for the 
extraction of substrates from the ER to the cytoplasm, regardless of the composition of the ERAD complexes 
and/or pathways employed. Thus, any down-regulation of p97/VCP will be accompanied by a decreased MHC 
class I presentation of all ERAD-dependent antigens. Importantly, the involvement of ERAD in the supply of 
MHC class I-restricted peptides is not exclusively restricted to hydrophobic antigens. Hence, a major role for 
ERAD has also been described in the cross-presentation of soluble antigens by dendritic cells (DC)43–46, although 
the precise mechanisms by which internalized antigens use ERAD to gain access to the cytoplasm remain 
unclear. Interestingly, cross-presentation is not restricted to DC and may be also used by melanoma cells to 
Figure 4. Re-expression of p97/VCP reconstitutes Melan-A/MART-126-35 epitope presentation. (A) The 
UKRV-Mel-15a clone 18 as well as the UKRV-Mel-15a parental cells were transfected with an expression 
vector encoding the p97/VCP full-length protein, as indicated. After 24 h of transfection, cells were exposed to 
Melan-A/MART-126-35 CTL to evaluate their capacity to present the Melan-A/MART-126-35 epitope. Following 
a 6 h co-culture, the supernatants were harvested and tested for their TNF-α content by ELISA. Controls in this 
experiment consisted of unloaded T2 and T2 cells loaded with 5 μ M of the Melan-A/MART-126-35 synthetic 
peptide (right panel). Shown is one representative experiment out of three. **p < 0.01 vs UKRV-Mel-15a clone 
18 (left graph) or unloaded T2 cells (right graph) and #p < 0.05 vs UKRV-Mel-15a cells (Student’s t test).  
(B) Melanoma cells were subjected to protein extraction and whole cell extracts were resolved on SDS-PAGE 
followed by Western blotting using antibodies specific for p97/VCP and β -actin (loading control), as indicated.
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present antigens derived from secretory proteins such as the matrix metalloproteinase-2 (MMP2)560-568 epitope47. 
As expected, a role for ERAD has been suggested in the processing of this antigenic peptide48, although the 
implication of p97/VCP remains to be formally addressed. Our experiments demonstrate that re-expression of 
p97/VCP in CTL-resistant UKRV-Mel-15a clone 18 and Ma-Mel-63a clone 15 to normal levels was able to almost 
completely recover Melan-A/MART-126-35 epitope presentation. The expression of p97/VCP is not induced by 
cytokines and it is not clear at the moment why its expression may be so influenced by exposure of melanoma 
cells to Melan-A/MART-126-35 CTL. In any case, the down-regulation of ERAD is of general importance, as it 
will affect not only the presentation of the Melan-A/MART-126-35 epitope but also the presentation of all other 
membrane protein-derived tumor epitopes generated by the ERAD pathway. Our data suggest that, in order to 
minimize or circumvent rapid immune evasion upon T-cell therapy, those tumor epitopes should be chosen and 
simultaneously targeted by T cells that are derived from separate antigens, which are degraded and processed by 
distinct degradation pathways. In this context, the option to target antigens whose degradation does not primarily 
rely on the UPS appears indeed particularly attractive. In view of the UPS, and a fortiori, p97/VCP as a major 
target whose deregulation might facilitate tumor escape, future research efforts may also address the functional 
relevance of proteasome-independent MHC class I tumor peptides in immunotherapy.
Material and Methods
Cell culture and immune selection of melanoma cells. The T2 lymphoblastoid cell line as well as the 
human melanoma cell lines Ma-Mel-91 cells (Melan-A/MART-1−, HLA-A*0201), UKRV-Mel-15a (Melan-A/
MART-1+, HLA-A*0201), Ma-Mel-63a (Melan-A/MART-1+, HLA-A*0201) and immune selected cell clones 
derived from UKRV-Mel-15a or Ma-Mel-63a were cultivated in RPMI supplemented with 10% fetal bovine serum 
(Biochrom AG, Germany). Authentication of these cell lines was ensured by genetic profiling on genomic DNA 
at the Institute for Forensic Medicine (University Hospital Essen) using the AmpFLSTR-Profiler Plus kit (Applied 
Biosystems)49. To obtain UKRV-Mel-15a or Ma-Mel-63a clones resistant to lysis by HLA-A*0201-restricted 
Melan-A/MART-126-35-specific CTL, melanoma cells were co-cultured for 5 h with a Melan-A/MART-126-35-
specific CTL clone raised against the ELAGIGILTV mutant peptide at a ratio of 1:50. Resistant melanoma cells 
were kept in culture for two weeks, followed by one or two additional rounds of co-incubation with Melan-A/
Figure 5. Melan-A/MART-126-35 epitope presentation in the immune challenged UKRV-Mel-15a clone 18 is 
not rescued by VIMP over-expression. (A) The UKRV-Mel-15a clone 18 was subjected to a 24-h transfection 
with an empty vector (mock) or expression vectors encoding VIMP, p97/VCP or p97QQ/VCP, as indicated. 
Whole cell-extracts were resolved on 15% SDS-PAGE and analysed by western-blotting using antibodies against 
VIMP, p97/VCP and β -actin (loading control). (B) The ability of the UKRV-Mel-15a clone 18 over-expressing 
VIMP, p97/VCP or p97QQ/VCP to present the Melan-A/MART-126-35 antigenic peptide was evaluated by 
exposing them to Melan-A/MART-126-35-specific CTL followed by IFN-γ measurement in the supernatants by 
ELISA. In addition, cells were pulsed with 1 μ M of the Melan-A/MART-126-35 synthetic peptide, as a positive 
control. Shown is one representative experiment out of two. **p < 0.01 vs UKRV-Mel-15a clone 18 (mock) 
(Student’s t test).
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MART-1-specific CTL. UKRV-Mel-15a and Ma-Mel-63a cells were then cloned by limiting dilution at 0,3 cells/well 
in 96 well plates and single clones were expanded for further analysis.
Preparation of RNA, microarray hybridization, and data analysis. Microarrays hybridizations 
were conducted, as previously described50. Briefly, total RNA was extracted, amplified and labelled with bio-
tin (Message AmpII-Biotin enhanced Kit, Ambion). The Human U133 2.0 Plus-Array (Affymetrix) was cus-
tom hybridized and evaluated by standard procedures (Signature Diagnostics). Raw data files were deposited 
on NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) under the accession number 
GSE75929.
Transfection of melanoma cells for antigen presentation analysis. Melanoma cells were trans-
fected with expression plasmids encoding pMART-1 wild-type, p97 wild-type, p97QQ, a dominant negative 
p97QQ mutant (both provided by T. Rapoport, Department of Cell Biology, Harvard Medical School, Boston, 
MA) (all cloned into pcDNA3.1 vector, Invitrogen)16 or control plasmid pcDNA3.1. Transfection was per-
formed using Lipofectamine 2000 (Invitrogen) following manufacturer’s instructions. After 24–48 h of transfec-
tion, cells were harvested for further studies. For siRNA transfection, HighPerFect Reagent (Roche) was used. 
Cells were incubated for 72 h with ON-TARGET-plus SMART pools siRNA duplexes targeting HERP (human 
HERPUD1), p97/VCP or non-targeting (control) siRNA (all purchased from Dharmacon Inc.). VIMP-siRNA 
(5′-CTGGCGGATGAGGCTAAGAAT-3′) was purchased from Qiagen.
Figure 6. Analysis of Ma-Mel-63a melanoma cell clones resistant to Melan-A/MART-126-35-specific 
CTL lysis. (A) The Ma-Mel-63a cells (Melan-A/MART-1+, HLA-A*0201+) were tested for their ability to 
endogenously process and present the Melan-A/MART-126-35 antigenic peptide by cultivating them with 
Melan-A/MART-126-35 CTL. Additionally, Ma-Mel-63a cells were either transfected with pcDNA3.1 plasmid or 
an expression vector encoding the p97/VCP full-length protein. After 6 h, supernatants were harvested and their 
content for TNF-α was determined by ELISA. Controls in this assay consisted in non-pulsed T2 cells (negative) 
and T2 cells pulsed with 5 μ M of the 10-mer synthetic peptide (right panel). **p < 0.01 vs unloaded T2 cells 
(Student’s t test) (B) The Ma-Mel-63a clones 3,4,9,13,15,16,26,31 and 33 were tested for their ability to present 
the Melan-A/MART-126-35 epitope by culturing them with Melan-A/MART-126-35-specific CTL. Activation 
of CTL was assessed by measuring the TNF-α -content in the supernatants by ELISA after 6 h of co-culture. 
*p < 0.05 and **p < 0.01 vs the Ma-Mel-63a parental cell line (Student’s t test). (C) The parental Ma-Mel-63a 
cell line as well as the Ma-Mel-63a clones were subjected to protein extraction and subsequent western blotting 
using anti-p97/VCP and anti-β -actin (loading control) antibodies. The steady-state expression levels of p97/
VCP in the parental Ma-Mel-63a cell line and the Ma-Mel-63a clones were visualized by densitometric analysis. 
The band intensity of p97/VCP was normalized to that of β -actin and subsequently expressed as fold-changes 
compared to the Ma-Mel-63a parental cell line which was set as 1.
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Generation of Melan-A/MART-126-35-specific CD8+T cell clone. A HLA-A*0201-restricted Melan-A/
MART- 1-specific CD8+T cell clone was generated against the ELAGIGILTV mutant peptide as described pre-
viously51,52. For antigen presentation analysis, melanoma cells were incubated with Melan-A/MART-1-specific T 
cells for 6 h at an E:T ratio of 1:1 or 8:1, as previously described53. As positive control, target cells were loaded with 
5 μ M of the Melan-A/MART-126-35 ELAGIGILTV peptide for 1 or 2 h. Activation of Melan-A/MART-1-specific 
CTL was assessed by quantification of secreted TNF-α or IFN-γ by ELISA as described below.
ELISA. ELISA for TNF-α or IFN-γ was performed following the manufacturer’s instructions (BD Biosciences). 
Diluted (1:5) supernatants from CTL-experiments were added to 96 wells pre-coated with anti-TNF-α or 
anti-IFN-γ antibodies in duplicates and supplemented with secondary antibodies and streptavidin-bound POD 
for 1 h. Plates were washed and incubated for 30 min with TMB substrate (BD Biosciences). Optical density was 
determined at 450 nm.
Immunoblot analysis. Cells were lysed in Mammalian Protein Extraction Reagent (Pierce) containing 
Complete Protease Inhibitors (Roche). Proteins were separated on SDS-PAGE and immunoblotted with antibod-
ies specific for p97/VCP (provided by R. Hartmann-Petersen), VIMP, Derlin-1 (both provided by T. Rapoport), 
HERP (laboratory stock)14, GAPDH (Santa Cruz), Melan-A/MART-1 (Novocastra), β -actin (Santa Cruz), 
β 5i/LMP7, β 1i/LMP2, β 2i/MECL-1 (laboratory stock), TAP1 (Rockland) and TAP2 (NBL). Detection was carried 
out by enhanced chemiluminescence. Densitometric analysis was performed using ImageJ NIG software.
Flow cytometry analysis. HLA-A*0201 surface expression as well as intracellular Melan-A/MART-1 anti-
gen expression was determined by flow cytometry using a FITC-conjugated mAb BB7.2 for HLA-*0201 and a 
Melan-A/MART-1 antibody (NovoCastra) followed by staining with FITC-conjugated anti-mouse antibody (BD 
Biosciences) for Melan-A/MART-1. Cells were analyzed on a Becton Dickinson FACSCalibur with Cell Quest 
software (BD Biosciences).
CTL assay. After removing unbound peptides by three washing steps with PBS, Melan-A/MART-1 epitope 
presentation was determined in a TNF-α release assay. CTL-mediated lysis of resistant melanoma cell clone was 
investigated by incubating melanoma cells with 5 μ M of the synthetic Melan-A/MART-126-35 ELAGIGILTV pep-
tide for 2 h, followed by a standard51Cr release assay, as previously described54.
Cycloheximide (CHX) chase. HeLa cells were exposed to either non-targeting (control) or p97/VCP siRNA 
for 24 h prior to a subsequent transfection with an expression plasmid encoding the Melan-A/MART-1 full-length 
protein. After 24 h of transfection, 50 μ g/ml of CHX was added to all samples (0 h chase). Cells were collected after 
1, 2, 4 and 8 h and Western blot analysis was performed for each time point using antibodies specific for p97/VCP, 
Melan-A/MART-1 and GAPDH (loading control).
Figure 7. Melan-A/MART-126-35 epitope presentation in the immune challenged Ma-Mel-63a clone 15 is 
rescued by p97/VCP over-expression. (A) The protein content of VIMP, HERP and Derlin-1 in the Ma-Mel-
63a parental cell line and the Ma-Mel-63a clones 9, 15 and 26 was assessed by western-blotting, as indicated. 
Equal protein loading was ensured by probing the membrane with an anti-β -actin antibody. (B) The Ma-Mel-
63a clone 15 was transfected with pcDNA3.1/p97/VCP for 24 h, as indicated and subsequently co-cultured 
with Melan-A/MART-126-35 CTL for further 6 h. The ability of these cells to present the Melan-A/MART-126-35 
antigenic peptide was evaluated by measuring the content of TNF-α in the supernatants by ELISA. Control in 
this experiment consisted in the Ma-Mel-63a parental melanoma cell line transfected with the empty pcDNA3.1 
plasmid or not. Shown is one representative experiment out of two. **p < 0.01 vs Ma-Mel-63a clone 15 and 
##p < 0.01 vs Ma-Mel-63a cells (Student’s t test). (C) The Ma-Mel-63a clone 15 transfected or not with p97/VCP 
as well as the Ma-Mel-63a parental cell line were analyzed for their p97/VCP content by western-blotting, as 
indicated. GAPDH was used as loading control.
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